E
Durham biotechnology company developing selective small-molecule TAK1 inhibitors for autoimmune, inflammatory, fibrotic, neurodegenerative, and infectious diseases.
At a glance
- HQ: Durham
- Sector: Biotech
- Stage: Grant
- Affiliation: Duke
This is the free preview.
The full profile is for members: founders, funding history, investor connections, and recent signals. Accounts are free; I review every request, usually within 48 hours.